Opus Genetics (IRD) Price & Analysis

Compare

1,046 Followers

IRD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.65 - $1.75

Previous CloseN/A

Volume154.21K

Average Volume (3M)192.59K

Market Cap

$66.22M

Enterprise Value$28.28M

Total Cash (Recent Filing)$32.43M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.66

Next Earnings

Nov 18, 2025

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding59,661,198

10 Day Avg. Volume100,163

30 Day Avg. Volume192,593

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.43

Enterprise Value/Revenue1.83

Enterprise Value/Gross Profit2.26

Enterprise Value/Ebitda-0.48

Forecast

1Y Price Target

$6.00

Price Target Upside408.47% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical TrialsRyzumvi succeeded in its Ph3 VEGA-3 trial in patients with presbyopia, showing durable benefit for up to 12 hours in 27% of patients.

Market AdvantageThere are no other available therapies for this indication, enhancing Ryzumvi's potential market advantage.

Safety ProfileRyzumvi differentiates itself based on its safety profile, an important factor for its competitive positioning.

Bears Say

Financial RisksRisks to the investment thesis include potential failure of products to achieve peak commercial revenue estimates and the failure to secure capital resources to fund operations.

Opus Genetics News

Opus Genetics reports Q2 EPS (12c) vs (30c) last year

Reports Q2 revenue $2.9M, consensus $4.27M. “We’ve made significant progress across our pipeline, with multiple clinical and regulatory...

2d ago

IRD

Opus Genetics, Global RDH12 Alliance partner to advance RDH12 gene therapy

Opus Genetics (IRD) announced a strategic partnership with the Global RDH12 Alliance to advance Opus’ gene therapy program...

23d ago

IRD

Opus Genetics, Global RDH12 Alliance partner to advance RDH12 gene therapy

Opus Genetics (IRD) announced a strategic partnership with the Global RDH12 Alliance to advance Opus’ gene therapy program...

23d ago

IRD

Opus Genetics: Promising Clinical Trials and Strategic Partnerships Drive Buy Rating

Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Caufield from...

4h ago

IRD

Opus Genetics Secures Funding for Gene Therapy Development

Opus Genetics ( ($IRD) ) has shared an announcement. On July 22, 2025, Opus Genetics entered into a...

23d ago

IRD

Opus Genetics: Strategic Collaborations and Promising Trial Outcomes Justify Buy Rating

Opus Genetics (IRD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today....

2M ago

IRD

Opus Genetics: Promising Developments and Strong Pipeline Justify Buy Rating

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on IRD stock, giving a Buy rating today. Debanjana...

2M ago

IRD

Opus Genetics Announces Positive Phase 3 Trial Results

Opus Genetics ( ($IRD) ) just unveiled an announcement. On June 26, 2025, Opus Genetics announced positive topline...

2M ago

IRD

Opus Genetics’ Phentolamine Ophthalmic Solution meets primary Phase 3 endpoint

Opus Genetics (IRD) announced positive topline results from VEGA-3, its second pivotal Phase 3 trial evaluating Phentolamine Ophthalmic...

2M ago

IRD

Opus Genetics Secures $2M Funding for Gene Therapy

Opus Genetics ( ($IRD) ) has provided an announcement. On June 23, 2025, Opus Genetics announced a funding...

2M ago

IRD

Opus Genetics awarded non-dilutive funding from the RD Fund

Opus Genetics (IRD) disclosed that the Retinal Degeneration Fund has entered into a funding agreement with Opus providing...

2M ago

IRD

Opus Genetics Secures Funding for MERTK Program

Opus Genetics ( ($IRD) ) just unveiled an update. On June 13, 2025, Opus Genetics entered into a...

2M ago

IRD

Opus Genetics initiated with a Buy at Lucid Capital

Lucid Capital analyst Dev Prasad initiated coverage of Opus Genetics (IRD) with a Buy rating and $5 price...

2M ago

IRD

Opus Genetics’ Ryzumvi Shows Promising Phase 3 Results, Reinforcing Buy Rating

Analyst Debanjana Chatterjee of JonesTrading reiterated a Buy rating on Opus Genetics (IRD – Research Report), retaining the...

2M ago

IRD

IRD FAQ

What was Opus Genetics’s price range in the past 12 months?

Opus Genetics lowest stock price was $0.65 and its highest was $1.75 in the past 12 months.

What is Opus Genetics’s market cap?

Opus Genetics’s market cap is $66.22M.

When is Opus Genetics’s upcoming earnings report date?

Opus Genetics’s upcoming earnings report date is Nov 18, 2025 which is in 95 days.

How were Opus Genetics’s earnings last quarter?

Opus Genetics released its earnings results on Aug 13, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.205 by $0.085.

Is Opus Genetics overvalued?

According to Wall Street analysts Opus Genetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Opus Genetics pay dividends?

Opus Genetics does not currently pay dividends.

What is Opus Genetics’s EPS estimate?

Opus Genetics’s EPS estimate is -0.2.

How many shares outstanding does Opus Genetics have?

Opus Genetics has 59,661,198 shares outstanding.

What happened to Opus Genetics’s price movement after its last earnings report?

Opus Genetics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.205. Following the earnings report the stock price went down -0.901%.

Which hedge fund is a major shareholder of Opus Genetics?

Currently, no hedge funds are holding shares in IRD

Opus Genetics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-200.57%

Trailing 12-Months

Asset Growth

-13.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Opus Genetics

Opus Genetics (IRD) is a biotechnology company focused on developing gene therapies for inherited retinal diseases. The company operates within the biopharmaceutical sector, concentrating on creating innovative treatments aimed at restoring vision for patients affected by genetic eye disorders. Its core products are gene therapy solutions that target specific genetic mutations responsible for retinal diseases.

Opus Genetics (IRD) Earnings & Revenues

Historic Earnings Reports

IRD Stock 12 Month Forecast

Average Price Target

$6.00

▲(408.47% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","-1":"-$1","1.5":"$1.5","6.5":"$6.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.5,4,6.5,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.94,1.483076923076923,2.0261538461538464,2.5692307692307694,3.1123076923076924,3.6553846153846155,4.1984615384615385,4.741538461538462,5.284615384615385,5.827692307692308,6.3707692307692305,6.913846153846155,7.456923076923077,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.94,1.3292307692307692,1.7184615384615385,2.1076923076923078,2.496923076923077,2.8861538461538463,3.2753846153846156,3.664615384615385,4.053846153846154,4.443076923076923,4.832307692307692,5.2215384615384615,5.610769230769231,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.94,1.2523076923076923,1.5646153846153847,1.876923076923077,2.189230769230769,2.5015384615384617,2.813846153846154,3.1261538461538465,3.4384615384615387,3.750769230769231,4.063076923076924,4.375384615384616,4.687692307692307,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.53,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.64,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >